Hepatic & Liver Research

Advancing Hepatic Impairment Clinical Research

Hepatic impairment affects millions worldwide and can significantly impact medication metabolism, safety, and treatment outcomes. CenExel partners with sponsors to conduct specialized liver and hepatic impairment studies with precision, regulatory expertise, and diverse patient access across multiple clinical sites.

Studies Conducted
0 +
Trial Participants
0 +
Active Sites
0 +
Overview

Specialized Hepatic Impairment Research Expertise

CenExel provides comprehensive support for hepatic impairment and liver-focused clinical trials through experienced investigators, advanced operational infrastructure, and access to diverse patient populations. Our teams support studies ranging from mild to severe hepatic impairment, helping sponsors evaluate pharmacokinetics, safety, tolerability, and dosing strategies with confidence.

Conditions Covered

Hepatic Conditions We Research

Our hepatic impairment research programs support a broad range of liver-related conditions and metabolic disorders.

  • Hepatic Impairment (Mild, Moderate, Severe)
  • Nonalcoholic Fatty Liver Disease (NAFLD)
  • Nonalcoholic Steatohepatitis (NASH)
  • Liver Cirrhosis
  • Chronic Liver Disease
  • Hepatitis B
  • Hepatitis C
  • Alcohol-Related Liver Disease
Our Approach

Why Sponsors Choose CenExel for Hepatic Research

CenExel delivers operational excellence, scientific expertise, and high-quality data solutions for hepatic impairment clinical programs.

01

Hepatic Study Expertise

Our teams support hepatic impairment protocols with extensive experience in PK sampling, safety monitoring, and liver-specific assessments.

02

Faster Patient Recruitment

Our multi-site network enables rapid enrollment of patients across varying levels of hepatic impairment severity.

03

Diverse Patient Access

We provide access to broad and diverse patient populations to improve study representation and real-world applicability.

04

Regulatory-Ready Data

CenExel maintains high standards in data quality, compliance, and operational execution for successful submissions.

Phase Coverage

Supported Hepatic Research Trial Phases

CenExel supports early and late-phase hepatic impairment studies — from first-in-human and pharmacokinetic studies through Phase IV post-marketing trials.

Active across all phases
  • Phase I
  • Phase II
  • Phase III
  • Phase IV

Our experienced investigators and clinical operations teams provide scientific guidance and operational support for hepatic impairment studies across all development stages.

Hepatic Research Task Force

CenExel supports sponsors conducting hepatic impairment and liver disease studies with experienced investigators, centralized operations, and specialized patient recruitment capabilities.

Active Sites

18 Sites

CenExel Phoenix
CenExel Anaheim
CenExel Atlanta
CenExel Marlton
CenExel Gaithersburg

Our Blog